ABBOTT LABORATORIES
ABTNYSETrading Snapshot
- Day Range
- $102.82 β $105.50
- 52-Week Range
- $81.97 β $131.49
- Volume (shares)
- 7,292,834
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.73B
- Next Earnings
- 2027-01-20
Fundamentals Snapshot
- Annual Revenue
- $44.33B
- Last Q Revenue
- $13.01B
- P/E Ratio
- 38.5
- P/S Ratio
- 3.8x
- EPS (TTM)
- $2.70
- Dividend Yield
- 2.39%
- Dilution (1yr)
- +0.1%
ABBOTT LABORATORIES
ABTAbout ABBOTT LABORATORIES
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Abbott Has Raised Its Dividend for 54 Years. These 3 Healthcare Stocks Keep Paying More
One dividend streak spans five decades, another company barely paid anything until 2021, and a third pays out a fraction of its earnings. Three healthcare payers raised income this year, but their safety margins look ver

Abbott Has Lost More Than 10% This Year, and $1,000 From Five Years Ago Is Worth Less Than $950
Abbott bought a $21 billion cancer screening business and still watched investors flee. A buyer from a decade ago is thrilled, but newer shareholders face a harder question about what finally turns the story around.

Abbott (ABT) Up 1.3% Since Last Earnings Report: Can It Continue?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

3 Dividend Kings to Buy in November and Never Sell
Abbott boasts 54 straight years of dividend growth, and plans to spin off its troubled nutrition division could lead to a re-rating of the stock. McDonald's has raised its dividend for 50 years, and the stock should rebo

Abbott initiates VOYAGER clinical trial for investigational Encantorβ’ software-guided balloon-expandable TAVI system to treat aortic stenosis
Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performance Encantor

This Abbott Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.